PHARMACEUTICAL COMPOSITION FOR TREATING FLT3 MUTATION POSITIVE CANCER FLT3 MUTANT INHIBITOR AND USE OF SAID PHARMACEUTICAL COMPOSITION AND SAID INHIBITOR
The present invention addresses the problem of providing: a pharmaceutical composition for treating FLT3 mutation positive cancer; an FLT3 mutant inhibitor; and a use of the pharmaceutical composition and the inhibitor. Provided are: a pharmaceutical composition for treating FLT3 mutation positive cancer which contains as an active ingredient a compound represented by general formula [1] or a salt thereof; an FLT3 mutant inhibitor; an anti cancer agent; a method for predicting the therapeutic effect of the administration of a pharmaceutical composition containing a compound represented by general formula [1] or a salt thereof in a subject said method comprising a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by general formula [1] or a salt thereof can be applied said method comprising a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by general formula [1] or a salt thereof can be administered to a subject said method comprising a step of detecting the presence or absence of an FLT3 mutation.